NCT04639193View on ClinicalTrials.gov

Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

January 27, 2022

Study Completion Date

January 27, 2022

Conditions
OSAObstructive Sleep Apnea
Interventions
DRUG

Acetazolamide

Acetazolamide tablet (encapsulated)

DRUG

Eszopiclone

Eszopiclone tablet (encapsulated)

DRUG

Placebo

Sugar capsule manufactured to match encapsulated Acetazolamide/Eszopiclone

DRUG

Venlafaxine

Venlafaxine capsule

Trial Locations (2)

92037

Altman Clinical and Translational Research Institute Building, La Jolla

92121

UCSD Health - Pulmonary and Sleep Clinic, La Jolla

All Listed Sponsors
collaborator

American Thoracic Society

OTHER

lead

University of California, San Diego

OTHER

NCT04639193 - Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea | Biotech Hunter | Biotech Hunter